# Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis

> **NCT00279760** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 210 (—)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Belatacept
- **DRUG:** Abatacept

## Key facts

- **NCT ID:** NCT00279760
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2002-03
- **Final completion:** —
- **Target enrollment:** 210 (—)
- **Last updated:** 2016-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00279760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00279760, "Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00279760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*